Global Information
회사소개 | 문의

전신성 홍반성 루푸스(SLE) : 파이프라인 리뷰

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

리서치사 Global Markets Direct
발행일 2018년 05월 상품 코드 264101
페이지 정보 영문 446 Pages
가격
US $ 2,000 ₩ 2,284,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,569,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,854,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전신성 홍반성 루푸스(SLE) : 파이프라인 리뷰 Systemic Lupus Erythematosus - Pipeline Review, H1 2018
발행일 : 2018년 05월 페이지 정보 : 영문 446 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

전신성 홍반성 루푸스(SLE)는 장기적인 만성 염증성 질환으로, 체내 면역계 시스템이 건강한 조직을 공격하는 자가면역질환입니다. 이로 인해 피부와 관절, 신장, 뇌 등의 장기가 영향을 받습니다. 확실한 원인은 알려져 있지 않지만, 다양한 요인이 유전, 환경, 성호르몬 등의 질환과 관련되어 있습니다. 증후는 다양하고 시간에 따라 변화하지만, 일반적인 것으로는 극심한 피로감, 관절 통증과 부종, 두통, 나비 모양 홍반이라고 불리는 뺨과 코의 발진, 탈모, 빈혈 등이 있습니다.

전신성 홍반성 루푸스(SLE : Systemic Lupus Erythematosus) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

전신성 홍반성 루푸스 개요

치료제 개발

치료제 평가

치료제 개발에 참여하고 있는 기업

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

KSM 17.07.24

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Araim Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Carna Biosciences Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Cells for Cells SA, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Kezar Life Sciences Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2018
  • Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2018

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

"Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia."

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 30, 25, 41, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 8 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Systemic Lupus Erythematosus - Overview
  • Systemic Lupus Erythematosus - Therapeutics Development
  • Systemic Lupus Erythematosus - Therapeutics Assessment
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
  • Systemic Lupus Erythematosus - Drug Profiles
  • Systemic Lupus Erythematosus - Dormant Projects
  • Systemic Lupus Erythematosus - Discontinued Products
  • Systemic Lupus Erythematosus - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research